Trial Profile

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amivantamab (Primary) ; Lazertinib (Primary) ; Carboplatin; Pemetrexed
Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; First in man; Pharmacokinetics; Registrational; Therapeutic Use
Acronyms CHRYSALIS
Sponsors Janssen Pharmaceutical KK; Janssen Research & Development

Most Recent Events

26 Mar 2024 Planned End Date changed from 31 Dec 2024 to 30 Jun 2025.
05 Dec 2023 Planned End Date changed from 30 Jan 2024 to 31 Dec 2024.
07 Nov 2023 Planned End Date changed from 26 Jan 2024 to 30 Jan 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com